1Lee JM, Ledermann JA, Kohn EC (2014) PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 25: 32-40.
2Pothuri B (2013) BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol 24: viii22-viii27.
3Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474 :609-615
4Kupfer GM (2013) Fanconi anemia: a signal transduction and DNA repair pathway. Yale J Biol Med 86:491-497.
5Kottemann MC, Smogorzewska A (2013) Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 493: 356-363.
6Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, et al. (2008) "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530-5536.
7 Monk BJ, Pujade-Lauraine E, Burger RA (2013) Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease. Ann Oncol 10: x53-x58.
8Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, et al. (2011) Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 105: 884-889.
9Stark D1, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L (2013) Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14: 236-243.
10Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496.
11Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS (2013) Chemokines in tumor progression and metastasis. Oncotarget 4: 2171-2185.
12Zhong C, Wang J, Li B, Xiang H, Ultsch M, et al. (2013) Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res 19: 4433-4445.
13Duda DG1, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, et al. (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17: 2074-2080.
14 Mosig RA, Lobl M, Senturk E, Shah H, Cohen S, et al. (2012) IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. J Ovarian Res 5:3.
15Hong F, Li Y, Xu Y, Zhu L (2013) Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res 41:64-71.
16Kan CW, Hahn MA, Gard GB, Maidens J, Huh JY, et al. (2012) Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 12:627.